James Wallace to Prognosis
This is a "connection" page, showing publications James Wallace has written about Prognosis.
Connection Strength
0.030
-
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Sep; 12(3):218-22.
Score: 0.016
-
Cancer in long-term care. Clin Geriatr Med. 2011 May; 27(2):301-27.
Score: 0.014